FLT3 (ITD/TKD)
FLT3 mutations, including ITD and TKD variants, are common drivers in acute myeloid leukemia. These alterations inform prognosis and selection of targeted FLT3 inhibitors.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where FLT3 (ITD/TKD) is defined directly in the indication labeling.
Approvals defined at the solid tumor level where FLT3 (ITD/TKD) is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report FLT3 (ITD/TKD) as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports FLT3 (ITD/TKD) as part of its biomarker panel.